Press release
2017-05-04
Xbrane Biopharma has recruited Susanna Helgesen as CFO and Head of Investor Relations at Xbrane. Susanna has previously been CFO at Dome Energy AB and analyst at Remium. Susanna will start on May 8, 2017 and will be part of Xbrane’s management team.
About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbranes’s headquarter is located in Stockholm and the company’s in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane’s certified advisor. For more information see www.xbrane.com.
For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 May 4 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/9d085913-f8c4-4298-9a31-49241d7712b8